Korsana Biosciences emerged from stealth with $175 million to advance antibodies across the blood-brain barrier for Alzheimer’s disease, targeting a 2027 clinical debut.
Longevity News
A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged.
Source: FierceBiotech - All • Published: 18 Feb 2026, 12:09
Continue exploring
Related longevity signals
Longevity TechnologyRetro Biosciences expands early trial for drug targeting Alzheimer’s, Parkinson’sA short news article about an early-stage clinical trial expansion testing higher doses of a candidate neurodegenerative drug, outlining safety and dosing goals and what readers can expect to learn.Nature - MainHuman brain organoids record the passage of time over multiple years - NatureReports multi‑year human cerebral organoid cultures that continue cell‑type specific maturation and record elapsed time via transcriptional and epigenomic changes.Longevity TechnologyAlzeCure’s $12m payday fuels new brain-aging therapyA business-focused article explaining a biotech licensing and investment deal that hands a brain-aging drug platform to a better-funded developer, and why that matters for future development.Lifespan.ioHow Senescence Spreads Between Brain CellsHow different brain cell types send and respond to senescence signals, and what themes researchers investigate in that line of work.